DDInter770 DDInter1676
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Fluvoxamine {u} (Compound) resembles {v} (Compound) Ridogrel
Fluvoxamine {u} (Compound) binds {v} (Gene) CYP3A4
Fluvoxamine {u} (Compound) upregulates {v} (Gene) CCNA1
Fluvoxamine {u} (Compound) palliates {v} (Disease) endogenous depression
Fluvoxamine {u} (Compound) downregulates {v} (Gene) HERPUD1
Fluvoxamine {u} (Compound) causes {v} (Side Effect) Accommodation disorder
Fluvoxamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tenecteplase
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Phenylpropanolamine
Fluvoxamine (Compound) resembles Ridogrel (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene)
Fluvoxamine (Compound) upregulates CCNA1 (Gene)
Fluvoxamine (Compound) palliates endogenous depression (Disease)
Fluvoxamine (Compound) downregulates HERPUD1 (Gene)
Fluvoxamine (Compound) causes Accommodation disorder (Side Effect)
Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase
Fluvoxamine may lead to a major life threatening interaction when taken with Phenylpropanolamine